TNYA Latest Press Releases

-- September 14, 2026 --

Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Globe Newswire 8:30 AM

-- September 3, 2026 --

Tenaya Therapeutics to Participate in Upcoming September Investor Conferences Globe Newswire 4:30 PM

-- August 5, 2026 --

Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- August 4, 2026 --

Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference Globe Newswire 4:05 PM

-- July 14, 2026 --

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 9:00 PM

-- June 29, 2026 --

Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer Globe Newswire 8:30 AM

-- June 3, 2026 --

Tenaya Therapeutics Announces Interim Data from MyPEAK -1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms Globe Newswire 7:00 AM

-- June 2, 2026 --

Tenaya Therapeutics to Announce New Interim Data from MyPEAK -1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 Globe Newswire 4:30 PM

Market Data Delayed 15 Minutes